Key clinical point: The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.

Major finding: Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; P_interaction < .01).

Study details: Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi:  10.1186/s12885-022-09850-4

Key clinical point: The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.

Major finding: Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; P_interaction < .01).

Study details: Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi:  10.1186/s12885-022-09850-4

Key clinical point: The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.

Major finding: Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; P_interaction < .01).

Study details: Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi:  10.1186/s12885-022-09850-4

Key clinical point: The concomitant use of gastric acid suppressants (GAS) may be associated with poor survival outcomes in patients with non—small-cell lung cancer (NSCLC) receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors.

Major finding: Use of PD-1/PD-L1 inhibitors with vs without GAS worsened progression-free survival by 32% (hazard ratio [HR] 1.32; P < .001) and overall survival by 36% (HR 1.36; P < .001).

Study details: The data come from a meta-analysis of 10 retrospective studies and 1 prospective cohort study including 5892 patients with NSCLC who were receiving PD-1/PD-L1 inhibitors.

Disclosures: This study was supported by Anhui University Natural Science Research Project, China. The authors declared no conflicts of interest.

Source: Wang M et al. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. Int Immunopharmacol. 2022;110:108955 (Jun 21). Doi:  10.1016/j.intimp.2022.108955

Key clinical point: The concomitant use of gastric acid suppressants (GAS) may be associated with poor survival outcomes in patients with non—small-cell lung cancer (NSCLC) receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors.

Major finding: Use of PD-1/PD-L1 inhibitors with vs without GAS worsened progression-free survival by 32% (hazard ratio [HR] 1.32; P < .001) and overall survival by 36% (HR 1.36; P < .001).

Study details: The data come from a meta-analysis of 10 retrospective studies and 1 prospective cohort study including 5892 patients with NSCLC who were receiving PD-1/PD-L1 inhibitors.

Disclosures: This study was supported by Anhui University Natural Science Research Project, China. The authors declared no conflicts of interest.

Source: Wang M et al. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. Int Immunopharmacol. 2022;110:108955 (Jun 21). Doi:  10.1016/j.intimp.2022.108955

Key clinical point: The concomitant use of gastric acid suppressants (GAS) may be associated with poor survival outcomes in patients with non—small-cell lung cancer (NSCLC) receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors.

Major finding: Use of PD-1/PD-L1 inhibitors with vs without GAS worsened progression-free survival by 32% (hazard ratio [HR] 1.32; P < .001) and overall survival by 36% (HR 1.36; P < .001).

Study details: The data come from a meta-analysis of 10 retrospective studies and 1 prospective cohort study including 5892 patients with NSCLC who were receiving PD-1/PD-L1 inhibitors.

Disclosures: This study was supported by Anhui University Natural Science Research Project, China. The authors declared no conflicts of interest.

Source: Wang M et al. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. Int Immunopharmacol. 2022;110:108955 (Jun 21). Doi:  10.1016/j.intimp.2022.108955

Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).

Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P  =  .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P  =  .0086).

Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538

Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).

Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P  =  .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P  =  .0086).

Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538

Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).

Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P  =  .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P  =  .0086).

Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538

Key clinical point: Use of preoperative fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is linked to a longer overall survival in patients with stage IIIA or IIIB resectable non—small-cell lung cancer (NSCLC).

Major finding: Among patients who underwent vs did not undergo preoperative ¹⁸F-FDG PET/CT, those with stage IIIB and stage IIIA disease had 20% (adjusted hazard ratio [aHR] 0.80; 95% CI 0.71-0.90) and 10% (aHR 0.90; 95% CI 0.79-0.94) lower risks for mortality, respectively. Patients with stage I-II disease did not have a lower risk for mortality (aHR 1.19; 95% CI 0.89-1.30).

Study details: The data come from a Taiwanese retrospective cohort study of patients with resectable stage I-IIIB NSCLC who underwent (n = 6,754) and did not undergo (n = 6,754) preoperative ¹⁸F-FDG PET/CT.

Disclosures: This study was funded by the Lo-Hsu Medical Foundation and Lotung Poh-Ai Hospital, Taiwan. SY Wu is a member of the Taiwan Radiological Society and Taiwan Society for Therapeutic Radiology and Oncology. The other authors reported no relevant relationships.

Source: Chen W-M et al. Use of preoperative FDG PET/CT and survival of patients with resectable non–small cell lung cancer. Radiology. 2022 (Jun 21). Doi: 10.1148/radiol.212798

Key clinical point: Use of preoperative fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is linked to a longer overall survival in patients with stage IIIA or IIIB resectable non—small-cell lung cancer (NSCLC).

Major finding: Among patients who underwent vs did not undergo preoperative ¹⁸F-FDG PET/CT, those with stage IIIB and stage IIIA disease had 20% (adjusted hazard ratio [aHR] 0.80; 95% CI 0.71-0.90) and 10% (aHR 0.90; 95% CI 0.79-0.94) lower risks for mortality, respectively. Patients with stage I-II disease did not have a lower risk for mortality (aHR 1.19; 95% CI 0.89-1.30).

Study details: The data come from a Taiwanese retrospective cohort study of patients with resectable stage I-IIIB NSCLC who underwent (n = 6,754) and did not undergo (n = 6,754) preoperative ¹⁸F-FDG PET/CT.

Disclosures: This study was funded by the Lo-Hsu Medical Foundation and Lotung Poh-Ai Hospital, Taiwan. SY Wu is a member of the Taiwan Radiological Society and Taiwan Society for Therapeutic Radiology and Oncology. The other authors reported no relevant relationships.

Source: Chen W-M et al. Use of preoperative FDG PET/CT and survival of patients with resectable non–small cell lung cancer. Radiology. 2022 (Jun 21). Doi: 10.1148/radiol.212798

Key clinical point: Use of preoperative fluorine 18-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) is linked to a longer overall survival in patients with stage IIIA or IIIB resectable non—small-cell lung cancer (NSCLC).

Major finding: Among patients who underwent vs did not undergo preoperative ¹⁸F-FDG PET/CT, those with stage IIIB and stage IIIA disease had 20% (adjusted hazard ratio [aHR] 0.80; 95% CI 0.71-0.90) and 10% (aHR 0.90; 95% CI 0.79-0.94) lower risks for mortality, respectively. Patients with stage I-II disease did not have a lower risk for mortality (aHR 1.19; 95% CI 0.89-1.30).

Study details: The data come from a Taiwanese retrospective cohort study of patients with resectable stage I-IIIB NSCLC who underwent (n = 6,754) and did not undergo (n = 6,754) preoperative ¹⁸F-FDG PET/CT.

Disclosures: This study was funded by the Lo-Hsu Medical Foundation and Lotung Poh-Ai Hospital, Taiwan. SY Wu is a member of the Taiwan Radiological Society and Taiwan Society for Therapeutic Radiology and Oncology. The other authors reported no relevant relationships.

Source: Chen W-M et al. Use of preoperative FDG PET/CT and survival of patients with resectable non–small cell lung cancer. Radiology. 2022 (Jun 21). Doi: 10.1148/radiol.212798

Key clinical point: Circulating cell-free RNA (cfRNA) of the candidate transcript MORF4L2 demonstrates very good sensitivity and specificity for distinguishing patients with non—small-cell lung cancer (NSCLC) from healthy individuals.

Major finding: A greater concentration of MORF4L2 cfRNA was seen in patients with NSCLC compared with healthy donors (P < .0001). A cutoff value of 537.5 copies/mL of plasma was useful in distinguishing patients with NSCLC from healthy donors with very good sensitivity (0.73; 95% CI 0.61-0.82) and specificity (0.87; 95% CI 0.73-0.96). Low vs high levels of MORF4L2 cfRNA at baseline were associated with a better overall survival (hazard ratio 0.25; P  =  .009).

Study details: The data come from a cohort study of 41 patients with stage IV NSCLC, 38 patients with early-stage (stage I-III) NSCLC, and 39 healthy blood donors.

Disclosures: This study was supported by the European Transcan-2 project CEVIR (Cancer EVolution and Identification of Relapse-initiating cells) and the German Cancer Consortium. M Metzenmacher, JT Siveke, and M Schuler reported ties with ≥1 pharmaceutical companies. The other authors reported no conflicts of interest.

Source: Metzenmacher M et al. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thorac Cancer. 2022 (Jun 16). Doi: 10.1111/1759-7714.14540

Key clinical point: Circulating cell-free RNA (cfRNA) of the candidate transcript MORF4L2 demonstrates very good sensitivity and specificity for distinguishing patients with non—small-cell lung cancer (NSCLC) from healthy individuals.

Major finding: A greater concentration of MORF4L2 cfRNA was seen in patients with NSCLC compared with healthy donors (P < .0001). A cutoff value of 537.5 copies/mL of plasma was useful in distinguishing patients with NSCLC from healthy donors with very good sensitivity (0.73; 95% CI 0.61-0.82) and specificity (0.87; 95% CI 0.73-0.96). Low vs high levels of MORF4L2 cfRNA at baseline were associated with a better overall survival (hazard ratio 0.25; P  =  .009).

Study details: The data come from a cohort study of 41 patients with stage IV NSCLC, 38 patients with early-stage (stage I-III) NSCLC, and 39 healthy blood donors.

Disclosures: This study was supported by the European Transcan-2 project CEVIR (Cancer EVolution and Identification of Relapse-initiating cells) and the German Cancer Consortium. M Metzenmacher, JT Siveke, and M Schuler reported ties with ≥1 pharmaceutical companies. The other authors reported no conflicts of interest.

Source: Metzenmacher M et al. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thorac Cancer. 2022 (Jun 16). Doi: 10.1111/1759-7714.14540

Key clinical point: Circulating cell-free RNA (cfRNA) of the candidate transcript MORF4L2 demonstrates very good sensitivity and specificity for distinguishing patients with non—small-cell lung cancer (NSCLC) from healthy individuals.

Major finding: A greater concentration of MORF4L2 cfRNA was seen in patients with NSCLC compared with healthy donors (P < .0001). A cutoff value of 537.5 copies/mL of plasma was useful in distinguishing patients with NSCLC from healthy donors with very good sensitivity (0.73; 95% CI 0.61-0.82) and specificity (0.87; 95% CI 0.73-0.96). Low vs high levels of MORF4L2 cfRNA at baseline were associated with a better overall survival (hazard ratio 0.25; P  =  .009).

Study details: The data come from a cohort study of 41 patients with stage IV NSCLC, 38 patients with early-stage (stage I-III) NSCLC, and 39 healthy blood donors.

Disclosures: This study was supported by the European Transcan-2 project CEVIR (Cancer EVolution and Identification of Relapse-initiating cells) and the German Cancer Consortium. M Metzenmacher, JT Siveke, and M Schuler reported ties with ≥1 pharmaceutical companies. The other authors reported no conflicts of interest.

Source: Metzenmacher M et al. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. Thorac Cancer. 2022 (Jun 16). Doi: 10.1111/1759-7714.14540

Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).

Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.

Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.

Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.

Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946

Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).

Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.

Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.

Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.

Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946

Key clinical point: The presence of epidermal growth factor receptor (EGFR) mutation is associated with a longer median overall survival (OS) compared with absence of the EGFR mutation in patients with early-stage (stage I-IIIA) non—small-cell lung cancer (NSCLC).

Major finding: The presence vs absence of EGFR mutation was associated with a longer median OS (5.7 vs 4.4 years). The lower risk for all-cause mortality was consistent across all subgroups (stage at diagnosis, age, sex, comorbidity, and surgery receipt), with hazard ratios ranging from 0.48 to 0.83.

Study details: The data come from a Danish population-based cohort study involving 21,282 patients with NSCLC.

Disclosures: This study was funded by AstraZeneca. A Taylor and L Servidio reported being current or former employees of AstraZeneca. V Ehrenstein and K Eriksen are employees of Aarhus University or Aarhus University Hospital. E Jakobsen is an employee of Odense University Hospital.

Source: Ehrenstein V et al. Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark. Cancer Med. 2022 (Jun 20). Doi: 10.1002/cam4.4946

Key clinical point: Serum level of 25-hydroxyvitamin D (25[OH]D) was inversely associated with albuminuria as an indicator of diabetic nephropathy in patients with type 2 diabetes mellitus (T2D), with the prevalence of macroalbuminuria increasing when the serum 25(OH)D level was <20 ng/mL.

Major finding: A strong negative association was observed between the serum 25(OH)D level and severity of albuminuria (r, −0.257; P < .001), with the prevalence of vitamin D deficiency being 61.8%, 33.3%, and 24.0% in patients with macroalbuminuria, microalbuminuria, and normoalbuminuria, respectively.

Study details: This was a cross-sectional study including 200 patients with T2D, of which 100, 66, and 34 had normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively.

Disclosures: This study was supported by Shiraz University of Medical Sciences, Iran. The authors declared no competing interests.

Source: Zomorodian SA et al. Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:171 (Jul 4). Doi: 10.1186/s12902-022-01088-2

Key clinical point: Serum level of 25-hydroxyvitamin D (25[OH]D) was inversely associated with albuminuria as an indicator of diabetic nephropathy in patients with type 2 diabetes mellitus (T2D), with the prevalence of macroalbuminuria increasing when the serum 25(OH)D level was <20 ng/mL.

Major finding: A strong negative association was observed between the serum 25(OH)D level and severity of albuminuria (r, −0.257; P < .001), with the prevalence of vitamin D deficiency being 61.8%, 33.3%, and 24.0% in patients with macroalbuminuria, microalbuminuria, and normoalbuminuria, respectively.

Study details: This was a cross-sectional study including 200 patients with T2D, of which 100, 66, and 34 had normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively.

Disclosures: This study was supported by Shiraz University of Medical Sciences, Iran. The authors declared no competing interests.

Source: Zomorodian SA et al. Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:171 (Jul 4). Doi: 10.1186/s12902-022-01088-2

Key clinical point: Serum level of 25-hydroxyvitamin D (25[OH]D) was inversely associated with albuminuria as an indicator of diabetic nephropathy in patients with type 2 diabetes mellitus (T2D), with the prevalence of macroalbuminuria increasing when the serum 25(OH)D level was <20 ng/mL.

Major finding: A strong negative association was observed between the serum 25(OH)D level and severity of albuminuria (r, −0.257; P < .001), with the prevalence of vitamin D deficiency being 61.8%, 33.3%, and 24.0% in patients with macroalbuminuria, microalbuminuria, and normoalbuminuria, respectively.

Study details: This was a cross-sectional study including 200 patients with T2D, of which 100, 66, and 34 had normoalbuminuria, microalbuminuria, and macroalbuminuria, respectively.

Disclosures: This study was supported by Shiraz University of Medical Sciences, Iran. The authors declared no competing interests.

Source: Zomorodian SA et al. Assessment of the relationship between 25-hydroxyvitamin D and albuminuria in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22:171 (Jul 4). Doi: 10.1186/s12902-022-01088-2

Key clinical point: The sarcopenia index (SI; serum creatinine/serum cystatin C ratio) is significantly associated with the prevalence of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2D).

Major finding: After adjusting for all confounders, SI was significantly associated with the prevalence of subclinical atherosclerosis (adjusted odds ratio 0.95; P  =  .015).

Study details: The data come from a cross-sectional study of 174 patients with T2D, of which 43.7% were diagnosed with subclinical atherosclerosis.

Disclosures: The study received no specific funding. Some authors declared receiving honoraria, personal fees, r research grants from various sources.

Source: Hashimoto Y et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002910 (Jun 23). Doi: 10.1136/bmjdrc-2022-002910

Key clinical point: The sarcopenia index (SI; serum creatinine/serum cystatin C ratio) is significantly associated with the prevalence of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2D).

Major finding: After adjusting for all confounders, SI was significantly associated with the prevalence of subclinical atherosclerosis (adjusted odds ratio 0.95; P  =  .015).

Study details: The data come from a cross-sectional study of 174 patients with T2D, of which 43.7% were diagnosed with subclinical atherosclerosis.

Disclosures: The study received no specific funding. Some authors declared receiving honoraria, personal fees, r research grants from various sources.

Source: Hashimoto Y et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002910 (Jun 23). Doi: 10.1136/bmjdrc-2022-002910

Key clinical point: The sarcopenia index (SI; serum creatinine/serum cystatin C ratio) is significantly associated with the prevalence of subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2D).

Major finding: After adjusting for all confounders, SI was significantly associated with the prevalence of subclinical atherosclerosis (adjusted odds ratio 0.95; P  =  .015).

Study details: The data come from a cross-sectional study of 174 patients with T2D, of which 43.7% were diagnosed with subclinical atherosclerosis.

Disclosures: The study received no specific funding. Some authors declared receiving honoraria, personal fees, r research grants from various sources.

Source: Hashimoto Y et al. Relationship between serum creatinine to cystatin C ratio and subclinical atherosclerosis in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2022;10:e002910 (Jun 23). Doi: 10.1136/bmjdrc-2022-002910

Key clinical point: In patients with type 2 diabetes (T2D), initiating or switching to insulin degludec/ aspart (IDegAsp) from other antidiabetic treatments was associated with improved glycemic control, lower basal insulin dose requirement in insulin-experienced patients, and lower rates of hypoglycemia.

Major finding: Patients with T2D initiating or switching to IDegAsp had a significant reduction in glycated hemoglobin (estimated difference [Δ] −1.4%; P < .0001), basal insulin dose requirements in insulin-experienced participants (Δ −2.3 units; P  =  .0004), and rates of hypoglycemia (P < .001).

Study details: Findings are from a real-world, prospective study including 1102 patients with T2D who initiated or switched to IDegAsp from other antidiabetic treatments.

Disclosures: This study was funded by Novo Nordisk. Some authors declared being employees and shareholders of Novo Nordisk. Some authors declared receiving speaker or consulting honoraria, research contracts, and teaching or research sponsorships; being consultants; or serving as advisory board or speaker panel members for various sources, including Novo Nordisk.

Source: Fulcher GR et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022 (Jun 25). Doi: 10.1007/s12325-022-02212-3

Key clinical point: In patients with type 2 diabetes (T2D), initiating or switching to insulin degludec/ aspart (IDegAsp) from other antidiabetic treatments was associated with improved glycemic control, lower basal insulin dose requirement in insulin-experienced patients, and lower rates of hypoglycemia.

Major finding: Patients with T2D initiating or switching to IDegAsp had a significant reduction in glycated hemoglobin (estimated difference [Δ] −1.4%; P < .0001), basal insulin dose requirements in insulin-experienced participants (Δ −2.3 units; P  =  .0004), and rates of hypoglycemia (P < .001).

Study details: Findings are from a real-world, prospective study including 1102 patients with T2D who initiated or switched to IDegAsp from other antidiabetic treatments.

Disclosures: This study was funded by Novo Nordisk. Some authors declared being employees and shareholders of Novo Nordisk. Some authors declared receiving speaker or consulting honoraria, research contracts, and teaching or research sponsorships; being consultants; or serving as advisory board or speaker panel members for various sources, including Novo Nordisk.

Source: Fulcher GR et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022 (Jun 25). Doi: 10.1007/s12325-022-02212-3

Key clinical point: In patients with type 2 diabetes (T2D), initiating or switching to insulin degludec/ aspart (IDegAsp) from other antidiabetic treatments was associated with improved glycemic control, lower basal insulin dose requirement in insulin-experienced patients, and lower rates of hypoglycemia.

Major finding: Patients with T2D initiating or switching to IDegAsp had a significant reduction in glycated hemoglobin (estimated difference [Δ] −1.4%; P < .0001), basal insulin dose requirements in insulin-experienced participants (Δ −2.3 units; P  =  .0004), and rates of hypoglycemia (P < .001).

Study details: Findings are from a real-world, prospective study including 1102 patients with T2D who initiated or switched to IDegAsp from other antidiabetic treatments.

Disclosures: This study was funded by Novo Nordisk. Some authors declared being employees and shareholders of Novo Nordisk. Some authors declared receiving speaker or consulting honoraria, research contracts, and teaching or research sponsorships; being consultants; or serving as advisory board or speaker panel members for various sources, including Novo Nordisk.

Source: Fulcher GR et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non-interventional study across six countries. Adv Ther. 2022 (Jun 25). Doi: 10.1007/s12325-022-02212-3

Key clinical point: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes mellitus (T2D) is associated with a significantly lower risk for all-cause and cause-specific death compared with dipeptidyl peptidase 4 inhibitor (DPP4i) use.

Major finding: Patients receiving SGLT2i vs DPP4i had a lower risk for all-cause death (adjusted hazard ratio [aHR] 0.66; P < .001), cardiovascular death (aHR 0.68; P < .001), cancer death (aHR 0.73; P  =  .003), and noncancer and nonvascular death (aHR 0.62; P < .001).

Study details: This nationwide retrospective cohort study matched patients with T2D who initiated SGLT2i (n = 53,264) with those who initiated DPP4i (n = 53,264) using propensity score matching.

Disclosures: This study was partly supported by grants from China Medical University Hospital, Ditmanson Medical Foundation Chiayi Christian Hospital, and the Ministry of Science and Technology of Taiwan. No competing interests were declared.

Source: Chung M-C et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Sci Rep. 2022;12:10147 (Jun 16). Doi: 10.1038/s41598-022-13760-7

Key clinical point: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes mellitus (T2D) is associated with a significantly lower risk for all-cause and cause-specific death compared with dipeptidyl peptidase 4 inhibitor (DPP4i) use.

Major finding: Patients receiving SGLT2i vs DPP4i had a lower risk for all-cause death (adjusted hazard ratio [aHR] 0.66; P < .001), cardiovascular death (aHR 0.68; P < .001), cancer death (aHR 0.73; P  =  .003), and noncancer and nonvascular death (aHR 0.62; P < .001).

Study details: This nationwide retrospective cohort study matched patients with T2D who initiated SGLT2i (n = 53,264) with those who initiated DPP4i (n = 53,264) using propensity score matching.

Disclosures: This study was partly supported by grants from China Medical University Hospital, Ditmanson Medical Foundation Chiayi Christian Hospital, and the Ministry of Science and Technology of Taiwan. No competing interests were declared.

Source: Chung M-C et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Sci Rep. 2022;12:10147 (Jun 16). Doi: 10.1038/s41598-022-13760-7

Key clinical point: Sodium-glucose cotransporter 2 inhibitor (SGLT2i) use in patients with type 2 diabetes mellitus (T2D) is associated with a significantly lower risk for all-cause and cause-specific death compared with dipeptidyl peptidase 4 inhibitor (DPP4i) use.

Major finding: Patients receiving SGLT2i vs DPP4i had a lower risk for all-cause death (adjusted hazard ratio [aHR] 0.66; P < .001), cardiovascular death (aHR 0.68; P < .001), cancer death (aHR 0.73; P  =  .003), and noncancer and nonvascular death (aHR 0.62; P < .001).

Study details: This nationwide retrospective cohort study matched patients with T2D who initiated SGLT2i (n = 53,264) with those who initiated DPP4i (n = 53,264) using propensity score matching.

Disclosures: This study was partly supported by grants from China Medical University Hospital, Ditmanson Medical Foundation Chiayi Christian Hospital, and the Ministry of Science and Technology of Taiwan. No competing interests were declared.

Source: Chung M-C et al. Efficacy and safety of DBPR108 (prusogliptin) as an add-on to metformin therapy in patients with type 2 diabetes mellitus: A 24-week, multi-center, randomized, double-blind, placebo-controlled, superiority, phase III clinical trial. Sci Rep. 2022;12:10147 (Jun 16). Doi: 10.1038/s41598-022-13760-7